Skip to main content
Wolfson Institute of Population Health

Professor Borislava (Boby) Mihaylova, DPhil

Borislava (Boby)

Professor of Health Economics

Email: b.mihaylova@qmul.ac.uk
Telephone: Tel: +44 (0)20 7882 3863

Profile

I am a health economist with an academic background in Computer Science and Finance (Technical University-Sofia, Bulgaria), Health Economics (University of York, UK) and a DPhil in Public Health and Health Economics (University of Oxford, UK).

Early in my career I became involved in the development of the National Health Insurance system in Bulgaria and worked on the design and implementation of case-mix payment methods of hospital care. My MSc study in Health Economics at the University of York deepened my interest in health economics methods to assess value of health policies, services, and treatments. A NHS Training Fellowship enabled me to undertake DPhil at the University of Oxford studying the cost-effectiveness of statins in people at different risks of cardiovascular disease using large clinical studies. Thereafter, I investigated the value of statins, ezetimibe, blood pressure treatment, and niacin across patients by sex, age and cardiovascular risk, contributing to the widening of recommendations for statin and blood pressure treatment to people at lower cardiovascular risk, and discontinuing use of niacin due to safety concerns. 

At the Wolfson Institute of Population Health, QMUL, I lead research on impact of diseases and treatments on morbidity, mortality, health-related quality of life and healthcare/other resources and costs; cost-effectiveness of prevention and treatment strategies; and development of evaluative frameworks and disease models to assess net effects of policies and treatments. My team develops applied and methodological research across high burden disease areas and public health problems aiming to contribute robust evidence that reliably informs national and international health policy.

I teach graduate and undergraduate students and supervise PhD students. I am a co-director of the Wellcome Trust PhD Programme in Science “Health data in practice: human-centred science” and co-lead the MSc module “Health Economic Analyses”.

Teaching

Health Economic Analyses Module, MSc Global Health

Effective and Efficient Evaluation Module, MRes in Health Data in Practice

Research

Research Interests:

My research expertise lies across the areas of health economics and health technology assessment and includes primary and evidence synthesis research.  I have a particular interest in developing evaluative frameworks using individual people data sources to inform more targeted policy decisions.

 

Publications

Please click through to see a complete list of Borislava's publications

 Outstanding Publications 

 

 

    • Jumbe S, Madurasinghe VW, James WY et al. (2022), STOP— a training intervention to optimise treatment for smoking cessation in community pharmacies: cluster randomised controlled trial $nameOfConference


    • Keng MJ, Leal J, Bowman L et al. (2022), Hospital costs associated with adverse events in people with diabetes in the UK $nameOfConference


    • Thalmann I, Preiss D, Schlackow I et al. (2022), Antiplatelet therapy use for the secondary prevention of cardiovascular disease in 2009–2017: a population-wide retrospective cohort study of Scotland $nameOfConference


    • Wu R, Williams C, Zhou J et al. (2022), Benefit accrual with cardiovascular disease prevention and effects of discontinuation: a modelling study $nameOfConference


    • Mihaylova B, Wu R, Williams C et al. (2022), Cost-effectiveness of statin therapy in categories of patients in the UK $nameOfConference


    • Zhou J, Wu R, Williams C et al. (2022), Impact of cardiovascular events on primary and hospital care costs: findings from UK Biobank study $nameOfConference


    • Cholesterol Treatment Trialists' Collaboration (2022), Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. $nameOfConference


    • Schmierer K, Baker D, Nawaz T et al. (2022), 153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS) $nameOfConference


    • Castellani J, Kimbute O, Makasi C et al. (2022), Daily Life and Challenges Faced By Households With Permanent Childhood Developmental Disability in Rural Tanzania – A Qualitative Study $nameOfConference


    • Sammons E, Hopewell JC, Chen F et al. (2022), Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease $nameOfConference


    • Keng MJ, Armitage J, Bowman L et al. (2022), IDF21-0188 Impact of adverse events on hospital costs and health-related quality of life in people with diabetes $nameOfConference


    • Keng MJ, Leal J, Bowman L et al. (2022), Decrements in health-related quality of life associated with adverse events in people with diabetes $nameOfConference


    • Keng MJ, Leal J, Mafham M et al. (2022), Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort $nameOfConference


    • Levy M, Chen Y, Clarke R et al. (2022), Gender differences in use of invasive diagnostic and therapeutic procedures for acute ischaemic heart disease in Chinese adults $nameOfConference


    • Azhir A, Talebi S, Merino LH et al. (2022), BEHRTDAY: Dynamic Mortality Risk Prediction using Time-Variant COVID-19 Patient Specific Trajectories $nameOfConference

    • Wu R, Williams C, Schlackow I et al. (2022), CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA $nameOfConference

    • Roukas C, Syred J, Gordeev VS et al. (2022), Development and test-retest reliability of a new, self-report questionnaire assessing healthcare use and personal costs in people with inflammatory bowel disease: The Inflammatory Bowel Disease Resource Use Questionnaire (IBD-RUQ) $nameOfConference


    • Zhou J, Wu R, Williams C et al. (2022), EXCESS ANNUAL HOSPITAL COSTS DUE TO CARDIOVASCULAR EVENTS IN A CONTEMPORARY UK POPULATION TO INFORM HEALTH TECHNOLOGY ASSESSMENTS $nameOfConference

    • Zhou J, Wu R, Williams C et al. (2022), P55 Excess Annual Hospital Costs Due to Cardiovascular Events in a Contemporary UK Population to Inform Health Technology Assessments $nameOfConference


    • Wu R, Williams C, Schlackow I et al. (2022), P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data $nameOfConference


    • Thalmann I, Preiss D, Schlackow I et al. (2022), Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017 $nameOfConference


    • Azhir A, Talebi S, Merino LH et al. (2022), Using Shapes of COVID-19 Positive Patient-Specific Trajectories for Mortality Prediction $nameOfConference

    • Wu R, Rison S, Raisi-Estabragh Z et al. (2021), Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK $nameOfConference


    • Norton C, Syred J, Kerry S et al. (2021), Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial $nameOfConference


    • Wu R, Williams C, Schlackow I et al. (2021), A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts $nameOfConference


    • Wu R, Rison S, Raisi-Estabragh Z et al. (2021), Benefits from optimised antihypertensive and statin treatment in high risk people European Society of Cardiology Congress 2021

    • Wu R, Rison S, Raisi-Estabragh Z et al. (2021), Benefits from optimised antihypertensive and statin treatment in high risk people $nameOfConference


    • Lui NMJ, Williams C, Keng MJ et al. (2021), Impact of adverse events on quality of life and hospital costs in secondary cardiovascular disease prevention $nameOfConference


    • Leal J, Alva M, Gregory V et al. (2021), Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90) $nameOfConference


    • Halliday A, Bulbulia R, Bonati LH et al. (2021), Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy $nameOfConference


    • Perera R, Stevens R, Aronson JK et al. (2021), Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme $nameOfConference


    • Norton C, Syred J, Kerry S et al. (2021), Supported Online Self-Management Versus Care as Usual for Symptoms of Fatigue, Pain and Urgency/incontinence in Adults With Inflammatory Bowel Disease (IBD-BOOST): Study Protocol for a Randomized Controlled Trial. $nameOfConference


    • Thorn JC, Davies CF, Brookes ST et al. (2021), Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey $nameOfConference


    • Alonso Fernandez S, Tan M, Wang C et al. (2021), Impact of the 2003-2018 population salt intake reduction programme in England: a modelling study $nameOfConference


    • Colligan G, Tsocheva I, Scales J et al. (2021), Investigating the impact of London’s Ultra Low Emission Zone on children’s health: Children’s Health in London and Luton (CHILL): Protocol for a prospective parallel cohort study $nameOfConference


    • Shlipak MG, Tummalapalli SL, Boulware LE et al. (2021), The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference $nameOfConference


    • Schlackow I, Simons C, Oke J et al. (2020), Long-term health outcomes of people with reduced kidney function in the UK: A modelling study using population health data $nameOfConference


    • Lieberman D, Mangat H, Allen-Philbey K et al. (2020), Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS) $nameOfConference

    • Thalmann I, Preiss D, Schlackow I et al. (2020), Determinants of statin initiation and discontinuation in the secondary prevention of atherosclerotic cardiovascular disease in Scotland during 2009–2017 $nameOfConference


    • Tsiachristas A, West H, Oikonomou EK et al. (2020), Real world cost and health outcomes of patients presented with chest pain in England: which is the most cost-effective first-line test? $nameOfConference


    • O'Halloran R, Mihaylova B, Cairns BJ et al. (2020), BMI and Cause-Specific Hospital Admissions and Costs: The UK Biobank Cohort Study. $nameOfConference


    • Mach F, Baigent C, Catapano AL et al. (2020), 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk $nameOfConference


    • Levy M, Chen Y, Clarke R et al. (2020), Socioeconomic differences in health-care use and outcomes for stroke and ischaemic heart disease in China during 2009–16: a prospective cohort study of 0.5 million adults $nameOfConference


    • Mach F, Baigent C, Catapano AL et al. (2020), Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)) $nameOfConference


    • Mach F, Baigent C, Catapano AL et al. (2020), 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk $nameOfConference


    • Authors/Task Force Members, ESC National Cardiac Societies, ESC Committee for Practice Guidelines (CPG) (2020), Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205]. $nameOfConference


    • Roukas C, Tomini F, Mihaylova B (2019), P49 UK cost-effectiveness value pyramid of asthma interventions Driving quality improvement through education and training


    • Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies (2019), 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. $nameOfConference


    • Keng MJ, Tsiachristas A, Leal J et al. (2019), Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs $nameOfConference


    • Levy M, Chen Y, Clarke R et al. (2019), Declining socioeconomic inequalities in hospital care use and case fatality rates for stroke and ischaemic heart disease in China during 2009–16: a prospective study of 0·5 million adults $nameOfConference


    • Thorn J, Davies CF, Brookes ST et al. (2019), Essential items for a Health Economics Analysis Plan (HEAP): expert Delphi consensus survey $nameOfConference

    • Hopewell JC, Ibrahim M, Hill M et al. (2019), Impact of ADCY9 genotype on response to anacetrapib $nameOfConference


    • Oke JL, Feakins BG, Schlackow I et al. (publicationYear), Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysis $nameOfConference


    • Schlackow I, Kent S, Herrington W et al. (2019), Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. $nameOfConference


    • Schlackow I, Kent S, Herrington W et al. (publicationYear), Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease $nameOfConference


    • Edwards MR, Forbes G, MacDonald N et al. (2019), Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy with low-dose inotrope infusion compared with usual care in patients undergoing major elective gastrointestinal surgery. $nameOfConference


    • Keng MJ, Tsiachristas A, Leal J et al. (2019), Impact of variation in Type 2 diabetes care on health outcomes and healthcare costs $nameOfConference

    • Kent S, Aveyard P, Astbury N et al. (2019), Is Doctor Referral to a Low-Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity? $nameOfConference


    • MIHAYLOVA BA (2019), Efficacy and safety of statin therapy in older people: meta-analysis of individual participant data from 28 randomised controlled trials $nameOfConference


    • Oke JL, Feakins BG, Schlackow I et al. (2019), Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysis. $nameOfConference


    • Kent S, Jebb S, Gray A et al. (2018), Body Mass Index and use and costs of primary care services among women aged 55 to 79 years in England: a cohort and linked data study $nameOfConference


    • Castellani J, Mihaylova B, Siribié M et al. (2018), Household costs and time to treatment for children with severe febrile illness in rural Burkina Faso: The role of rectal artesunate 11 Medical and Health Sciences 1103 Clinical Sciences $nameOfConference


    • Herrington WG, Donovan K, Mihaylova B (2018), Authors’ reply $nameOfConference


    • Mihaylova B, Collaborative HT-R (2018), Assessing cardiovascular risk in people with atherosclerotic vascular disease on intensive statin therapy $nameOfConference

    • Mihaylova B (2018), P5083Assessing cardiovascular risk in people with atherosclerotic vascular disease on intensive statin therapy $nameOfConference


    • Jepson M, Elliott D, Conefrey C et al. (2018), An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment $nameOfConference


    • Marthi A, Donovan K, Haynes R et al. (2018), Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis $nameOfConference


    • Lokuge K, de Waard DD, Halliday A et al. (2018), Meta-Analysis of the Procedural Risks of Carotid Endarterectomy and Carotid Artery Stenting Over Time $nameOfConference


    • Morton RL, Schlackow I, Gray A et al. (2018), Impact of CKD on Household Income $nameOfConference


    • Lokuge K, de Waard DD, Halliday A et al. (2018), Meta-analysis of the procedural risks of carotid endarterectomy and carotid artery stenting over time $nameOfConference


    • Schlackow I, Kent S, Herrington W et al. (2017), A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease $nameOfConference


    • Bowman L, Hopewell JC, Chen F et al. (2017), Effects of anacetrapib in patients with atherosclerotic vascular disease $nameOfConference


    • Kent S, Fusco F, Gray A et al. (2017), Body mass index and healthcare costs: a systematic literature review of individual participant data studies $nameOfConference


    • Clayton GL, Smith IL, Higgins JPT et al. (2017), The INVEST project: Investigating the use of evidence synthesis in the design and analysis of clinical trials $nameOfConference


    • Schlackow I, Mihaylova B, Grp SHARPC (2017), A lifetime disease model based on an RCT: development, validation and applications $nameOfConference

    • Thorn J, Ridyard C, Hughes D et al. (2017), Health economics analysis plans: the current state of play $nameOfConference

    • Schlackow I, Gray A, Sharples L et al. (2017), Methods for extrapolation from clinical trial data to inform economic evaluations: a taxonomy $nameOfConference

    • de Waard DD, Halliday A, de Borst GJ et al. (2017), Choices of Stent and Cerebral Protection in the Ongoing ACST-2 Trial: A Descriptive Study. $nameOfConference


    • Kent S, Green J, Reeves G et al. (2017), Hospital costs in relation to body-mass index in 1·1 million women in England: a prospective cohort study $nameOfConference


    • Bowman L, Chen F, Sammons E et al. (2017), Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics $nameOfConference


    • Achelrod D, Gray A, Preiss D et al. (2017), Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe $nameOfConference


    • Herrington WG, Emberson J, Mihaylova B et al. (2016), Are statins useful in patients with advanced chronic kidney disease? – Authors' reply $nameOfConference


    • Thorn J, Ridyard C, Hughes D et al. (2016), PRM221 Health Economics Analysis Plans: Where Are We Now? $nameOfConference


    • Lokuge K, de Waard D, Bulbulia R et al. (2016), Procedural risks of carotid endarterectomy and carotid artery stenting have improved since 2005: Results from a systematic review of observational studies $nameOfConference

    • Herrington WG, Emberson J, Mihaylova B et al. (2016), Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials $nameOfConference


    • Kent S, Haynes R, Hopewell JC et al. (2016), Effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs $nameOfConference


    • Reith C, Blackwell L, Emberson J et al. (2016), Protocol for analyses of adverse event data from randomized controlled trials of statin therapy $nameOfConference


    • Mihaylova B, Schlackow I, Herrington W et al. (2016), Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: Results of the study of heart and renal protection (SHARP) $nameOfConference


    • Morton RL, Schlackow I, Staplin N et al. (2016), Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD $nameOfConference


    • Castellani J, Nsungwa-Sabiiti J, Mihaylova B et al. (2016), Impact of improving community-based access to malaria diagnosis and treatment on household costs $nameOfConference


    • Castellani J, Mihaylova B, Ajayi IO et al. (2016), Quantifying and valuing community healthworker time in improving access to malaria diagnosis and treatment $nameOfConference


    • Morton RL, Schlackow I, Mihaylova B et al. (2016), The impact of social disadvantage in moderate-to-severe chronic kidney disease: An equity-focused systematic review $nameOfConference


    • Lokuge K, Halliday A, Bulbulia R et al. (2015), Systematic review of randomised and observational evidence of effects of treatments of carotid stenosis to prevent stroke $nameOfConference


    • Morton RL, Schlackow I, Staplin N et al. (2015), FP329IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE $nameOfConference


    • Kent S, Schlackow I, Lozano-Kühne J et al. (2015), What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? $nameOfConference


    • Castellani J, Mihaylova B, Evers SMAA et al. (2015), Out-of-pocket costs and other determinants of access to healthcare for children with febrile illnesses: A case-control study in rural Tanzania $nameOfConference


    • Alva ML, Gray A, Mihaylova B et al. (2015), The impact of diabetes-related complications on healthcare costs: New results from the UKPDS (UKPDS 84) $nameOfConference


    • PLOS ONE Staff (2015), Correction: Out-of-Pocket Costs and Other Determinants of Access to Healthcare for Children with Febrile Illnesses: A Case-Control Study in Rural Tanzania. $nameOfConference


    • Fulcher J, O'Connell R, Voysey M et al. (2015), Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials $nameOfConference


    • Lokuge K, Halliday A, Bulbulia R et al. (2015), Systematic review of randomised and observational evidence of effects of treatments of carotid stenosis to prevent stroke $nameOfConference

    • Alva M, Gray A, Mihaylova B et al. (2014), The effect of diabetes complications on health-related quality of life: The importance of longitudinal data to address patient heterogeneity $nameOfConference


    • Schlackow I, Mihaylova B (2013), Developing a lifetime disease model from RCT data using parametric models with time-updated covariates $nameOfConference


    • Halliday A, Bulbulia R, Gray W et al. (2013), Status update and interim results from the asymptomatic carotid surgery trial-2 (ACST-2) $nameOfConference


    • Mihaylova B, Emberson J, Blackwell L et al. (2012), The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials $nameOfConference


    • Mihaylova B, Emberson J, Keech A et al. (2012), Authors' reply $nameOfConference


    • Heart Protection Study Collaborative Group (2011), Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. $nameOfConference


    • Mihaylova B, Briggs A, O'Hagan A et al. (2011), Review of statistical methods for analysing healthcare resources and costs $nameOfConference


    • Alva M, Gray AM, Mihaylova B et al. (2011), Outpatient Resource Utilization of Type-2 Diabetes Patients: New Evidence from the UKPDS $nameOfConference

    • Alva ML, Gray A, Mihaylova B et al. (2011), The effect of diabetes complications on health-related quality of life: estimating the bias due to unobserved heterogeneity using the UKPDS $nameOfConference


    • Buchanan J, Mihaylova B, Gray A et al. (2010), Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness $nameOfConference


    • Maude RJ, Mihaylova B, Warsame M et al. (2010), RECTAL AND INTRAVENOUS ARTESUNATE FOR SEVERE MALARIA: MODELLING THE IMPACT OF ARTEMISININ RESISTANCE $nameOfConference

    • Alva ML, Gray A, Mihaylova B et al. (2010), Estimating the quality of life impact of diabetes related complications: new results from the UKPDS $nameOfConference

    • Mihaylova B, Pitman R, Tincello D et al. (2010), Cost-effectiveness of duloxetine: The stress urinary incontinence treatment (SUIT) study $nameOfConference


    • Mihaylova B, Briggs A, Hlatky M et al. (2009), Statin cost-effectiveness in the United States for people at different vascular risk levels $nameOfConference


    • Briggs A, Mihaylova B, Sculpher M et al. (2007), Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study $nameOfConference


    • Mihaylova B, Briggs A, Armitage J et al. (2006), Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from randomised trial of 20 536 people $nameOfConference


    • Briggs A, Mihaylova B, Sculpher M et al. (2006), The cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study $nameOfConference

    • Briggs A, Mihaylova B, Sculpher M et al. (2006), The cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study $nameOfConference

    • Mihaylova B, Armitage J, Briggs A et al. (2005), Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial $nameOfConference

    • Mihaylova B, Briggs A, Armitage J et al. (2005), Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomised trial in 20 536 individuals $nameOfConference


    • Briggs A, Armitage J, Gray A et al. (2003), Economic evaluation of the Heart Protection Study $nameOfConference

    • Collins R, Armitage J, Parish S et al. (2003), MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. $nameOfConference


    • Heart Protection Study Collaborative Group (2002), MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. $nameOfConference


    • Heart Protection Study Collaborative Group (2002), MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. $nameOfConference


    • Bryant J, Loveman E, Chase D et al. (2002), Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: A systematic review and economic evaluation $nameOfConference


    • Bryant J, Cave C, Mihaylova B et al. (2002), Clinical effectiveness and cost-effectiveness of growth hormone in children: A systematic review and economic evaluation $nameOfConference


Supervision

  • Chris Roukas, Bowel Research UK, “Resource use, quality of life and value of self-management of IBD”
  • Anya Jacobs, Wellcome Trust PhD Programme in Science Health data in practice: human-centred science, “Developing a health economic framework for assessing asthma management strategies in UK primary care” 
Back to top